Compare NIO Inc. (NIO) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NIO Inc. vs Organon & Co. Common Stock — how do they compare? NIO Inc. trades at $3.4 (market cap $8.54B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: NIO Inc. is far larger — about 2.4× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while NIO Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold NIO Inc. for 81 Days and Organon & Co. Common Stock for 0 Days on average.
| NIO | OGN | |
|---|---|---|
Market Cap | $8.54B | $3.62B |
Volume | 34,684,903 | 2,892,999 |
Sector | Consumer Cyclical | Health |
52-Week High | $7.42 | $13.81 |
52-Week Low | $3.37 | $5.70 |
Typical Hold Time | 81 Days | 0 Days |
Enterprise Value | $6.43B | $11.04B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NIO trades at $3.41, down 1.73% on the day and near its 52-week low, reflecting a bearish technical trend. The company reported a net loss of $15.57 billion in 2025, though revenue grew to $87.49 billion and the net loss margin improved to -17.8%. Recent news highlights a strategic battery-swapping partnership with Geely, which could expand NIO's network but has weighed on the stock as investors assess profitability ahead of Q3 2026 earnings.
The outlook remains challenging due to persistent losses and intense EV competition, but analyst consensus is a Buy with a $6.23 price target, suggesting significant upside. Key risks include high debt, cash burn, and price wars in China's EV market, while opportunities lie in scaling the battery-swap network and potential margin improvement if delivery growth continues.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NIO Inc.
NIO Inc. manufactures and sells automobiles. The Company offers electric vehicles and parts, as well as provides battery charging services. NIO serves customers worldwide.
Read more on NIO →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
